作者： sarah

Over 100 attendees gathered at Suntec Singapore Convention & Exhibition Centre forONERHT Foundation’s 8th GAIL Forum 2025Forum featured high-level discussions on a wide range of topics including green leadership,ESG regulatory frameworks, carbon markets as well as the role of artificial intelligence (AI) inadvancing a sustainable futureSINGAPORE, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility vehicle of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”), successfully concluded its 8th edition of Greening ASEAN: Initiatives & Leadership (GAIL) Forum which was held on 22 July 2025 at Suntec Singapore Convention & Exhibition Centre.Photo by Ministry of Culture, Community and Youth (MCCY)The forum, themed “Industry, Business, and Regulatory Perspectives on Climate Mitigation and Adaptation,” welcomed over 100 participants, and featured a focused half-day programme of discussions and knowledge exchange.Ms.Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth & Ministry of Trade and Industry graced the event as Guest-of-Honour, delivering a keynote address.Ms.Kaylee Kwok, Chairman of ONERHT Foundation, said, “At GAIL 2025, we saw a powerful convergence of actionable insights and strategies from business and industry leaders as well as sustainability domain experts. These dialogues reflect the Foundation’s commitment in facilitating meaningful conversations that help shape ASEAN’s sustainable development journey.”The programme featured a dynamic fireside chat on “The Future of Green Leadership in ASEAN – How Businesses and Professional Services Can Drive Impact,” which explored real-world case studies on leadership models which aimed to drive sustainability agendas in corporate and professional spheres.A presentation on “Navigating ASEAN’s Green Transition: Legal and Policy Pathways” provided delegates with a comprehensive update on ASEAN’s progress in carbon markets under the Paris Agreement, key developments in ASEAN’s transition and disclosure frameworks, the evolution of corporate responsibility in the context of directors’ duties and climate justice in ASEAN.The session on “Developing and Investing in Carbon Markets in Asia: Business and Regulatory Perspectives” explored the current state of carbon markets in the region, investment opportunities and financial mechanisms, as well as the evolving legal frameworks, standards, and methodologies shaping carbon trading across Asia.Ms.Ch’ng Li-Ling, Director of RHT GRACE Institute, said, “Embedding sustainability into core governance, risk and compliance frameworks is essential. Our conversations today demonstrate that ESG is now foundational for the long-term success of any business.”Since its 2018 launch, the ONERHT Foundation GAIL Forum has grown as a central platform for catalysing sustainable development across ASEAN. With the Foundation marking its 10th anniversary this year, GAIL continues to reinforce cross-sector collaboration, capacity-building, and sustainability leadership in the region. To date, ONERHT Foundation has raised more than S$5.5 million to support over 35 charitable organisations.ONERHT Foundation LtdA Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours. Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively. The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised more than S$5.5 million to support more than 35 beneficiaries involved in education, the environment protection and sustainability, disadvantaged groups as well as the arts and sports.For more information, please visit www.onerht.foundationRHT GRACE Institute LtdRHT GRACE Institute (“RGI”) is a social enterprise launched by ONERHT Foundation Ltd in 2020. RGI seeks to establish a culture and creed of raising consciousness, encouraging ethical leadership, and growing a community of values-aligned mindfully ethical leaders, professionals, and businesses. The mission of RGI is anchored on the core principles based on Governance, Risk, AML, Compliance & ESG (G.R.A.C.E.) within an organisation’s business model, infusing these into its culture, and influencing and impacting leaders, professionals and individuals by setting a precedent and standard for what is expected in decision making and behaviour. The vision of RGI elevates an organization from good to great, embedding its principles in members’ business models, organizational strategy and decision-making processes and influencing them to become custodians and champions of G.R.A.C.E. principles.RGI runs the podcast “EthBeats: Lessons in G.R.A.C.E.ful Living”.For media enquiries, please contact:Melody Ong Email:  melody@waterbrooks.com.sg +65 8901 9780General enquiriesEmail: query@waterbrooks.com.sg +65 9338 8166  Copyright 2025 JCN Newswire via SeaPRwire.com.

Kawasaki and Nagoya, Japan, July 24, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Nagoya University, a member of the Tokai National Higher Education and Research System (THERS), have jointly developed a technology to encourage the use of new transportation services and eliminate transportation gaps. The “social acceptance model-based simulation (SAMSIM)” simulates how psychological factors influence residents' willingness to use new transportation options and combined with AI-powered digital rehearsal technology, it allows for proactive evaluation of strategies to ensure successful service adoption.Ride-sharing and self-driving cars have emerged as ways to address transportation gaps as populations age and driver shortages persist. However, the ease with which these new services are accepted varies depending on various psychological factors such as perceived safety, trust, and usefulness. To promote usage of these services, it is necessary to accurately understand the psychological factors that impact people's willingness to try them create measures that encourage behavioral change.Simulations using this technology showed that strategically timed and targeted public awareness campaigns could increase usage intent by approximately 20%. This research is a key outcome of the Fujitsu-Nagoya University Social Digital Twin Research Division at the Fujitsu Small Research Lab [1]. A demonstration of the technology will be accessible through the Fujitsu Research Portal starting August 1, 2025.Overview and background of the technologyThe "Social Acceptance Model," developed by Nagoya University, provides a framework for understanding the psychological drivers behind transportation choices. By integrating this model with Fujitsu's agent simulation digital rehearsal technology, which accurately reproduces and predicts human behavior on digital twins, the system can assess how various interventions – such as targeted advertising or other service improvements – will affect residents' perceptions and consequently their willingness to use the service.To verify the effectiveness of this technology, Fujitsu utilized the data from a field experiment of an on-demand ride-sharing taxi service conducted by Kawanishi Town in Nara Prefecture and CHUO FUKKEN CONSULTANTS CO.,LTD. in fiscal year 2023. In addition, Nagoya University conducted a 48-point survey to clarify the psychological factors that influence the intention to use on-demand ride-sharing taxis and obtained responses from approximately 1,200 people (15% of the local population).Based on this survey data, the simulation was built to replicate residents' choices regarding the service. The model succeeded in reproducing the actual usage trends of on-demand transportation in Kawanishi Town, achieving accuracy of 90%.Using this simulation, the two parties optimized two key measures – "public awareness activities" and "service expansion by increasing the number of vehicles" – for the two psychological factors that were estimated to have a strong impact on usage intention: "awareness of the service" and " perceived usefulness." The simulation specifically revealed that strategically improving the timing and frequency of the distribution of promotional materials and the increase of the number of available taxis could significantly reduce reservation failures and boost usage intention by approximately 20%, leading to a greater service sustainability.Figure 1: Overview of social acceptance model-based simulationFigure 2: Overview and results of the initiativesIsao Kita, Director of the Comprehensive Policy Division, Kawanishi Town, Nara Prefecture, comments:“I believe that pre-emptive consideration of transportation policies based on digital rehearsal technology will make it easier for local governments to consider measures amidst increasingly complex social issues. The possibilities are fascinating.”Future plansBy fiscal 2026, Fujitsu and Nagoya University will continue to conduct demonstration experiments and aim to develop this technology into a solution that suggests measures to improve adoption of new transportation services using data gained from small-scale resident surveys. Going forward, both parties will apply this technology to the design of public services in a wide range of fields, including healthcare, medicine, urban development, and environmental measures, in addition to the mobility sector, thereby improving people's well-being through converging technologies that combine the digital realm and humanities and social sciences.[1] Fujitsu Small Research Lab:Established in 2023. Fujitsu researchers reside or stay long-term at universities to accelerate joint research, discover new themes, develop human resources, and build medium- to long-term relationships with universities.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout Tokai National Higher Education and Research System – Nagoya UniversityBoasting a free and vibrant academic culture, Nagoya University has produced prominent leaders in Japanese industry through its globally renowned research and achievements, which have led to the awarding of Nobel Prizes to six Nagoya University scientists.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesTokai National Higher Education and Research System – Nagoya UniversityPhone: 052-789-5773kouho@t.mail.nagoya-u.ac.jp  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, Japan, July 24, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) today revealed some details of how it will support the World Athletics Championships Tokyo 25 (WCH Tokyo 25), which will be held from September 13 through 21, 2025. As an official global partner, Honda will contribute to the sustainability objectives of WCH Tokyo 25 and also by supporting athletes who strive to realize their dreams by pushing beyond their limits at this premier competition in the sport of track and field.The Honda theme for WCH Tokyo 25 is “Maximizing the excitement and inspiration from the athletes’ great performance, through the realization of an environmentally-responsible and safe event by providing a wide variety of mobility products equipped with innovative technologies.” Honda is planning to support the theme by providing its environmentally-responsible vehicles, including electric vehicles, to be used as the official vehicles of the WCH Tokyo 25.One such vehicle will be the Honda CR-V e:FCEV fuel cell electric vehicle, which will serve as the head umpire vehicle for both the men’s and women’s marathon races. The CR-V e:FCEV is a plug-in fuel cell vehicle that combines the benefits of a fuel cell vehicle—long driving range and short hydrogen refueling time—with plug-in battery charging, which further increases the convenience of driving the vehicle. During the WCH Tokyo 25, the CR-V e:FCEV will be fueled with “green hydrogen”—produced using renewable energy that emits no CO₂ even during production—to contribute to the environmentally-conscious event operations.Moreover, Honda will provide the Honda CUV e: for use as camera bikes covering both men’s and women’s marathon races. The electric personal commuter scooter model was designed to realize quiet and clean mobility in urban areas.In addition to these models, Honda plans to support and energize the event with a diverse lineup of Honda mobility products, including electric vehicles (EVs) and hybrid electric vehicles (HEVs).Honda CR-V e:FCEV with a special wrap displaying the WCH Tokyo 25 logoFurthermore, as a sponsor of the women’s bibs, the Honda corporate logo will appear on the bibs worn by all participating female athletes—approximately 1,000 in total.Honda special World Athletics websiteHonda today launched its special World Athletics website, within its global corporate website, where it will continuously share Honda stories and passion for supporting athletes who take on challenges in the WCH Tokyo 25, and introduce a wide variety of Honda vehicles serving active roles during the event.URL: https://global.honda/jp/WorldAthletics/ (Japanese) Launched on July 24https://global.honda/en/WorldAthletics/ (English) Launch on July 31Based on the Honda vision for its sports activities – “To increase the number of people who take on challenges through sports activities and make the lives of all people more enjoyable” – Honda will continue to support various athletes who take on challenges toward the realization of their own dreams. Copyright 2025 JCN Newswire via SeaPRwire.com.

- Rationalization of domestic production technologies and strengthening of the system in Japan for manufacturing divertor outer vertical targets for ITER- Seeking to contribute to the ITER Project and provide components for the prototype reactor for fusion energy and startup machinesTOKYO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, "Hitachi") and the National Institutes for Quantum Science and Technology (“QST”) began developing a second prototype, a full-scale mockup of an outer vertical target*1 which is one of the most important components of a divertor in January 2022. Divertors are important pieces of components used in the ITER fusion*2 experimental reactor that is under construction in Southern France. With streamlining the production method through measures such as the introduction of an automatic welding system as detailed below, we completed the second prototype in March 2025. Furthermore, we today announce that a high-heat-load sample of an outer vertical target has passed the rigorous certification test by the ITER Organization, which constructs and operates ITER as an international organization. Hitachi's production technologies have earned significant recognition following the preceding company which completed the first prototype with QST in July 2024.*1 QST will deliver 58 outer vertical targets to the ITER Organization. The preceding company manufactured 18 of these. The company that will manufacture the remaining 40 targets will be decided later.*2 Fusion is the source of the energy that keeps the sun shining. To realize fusion energy on Earth, it is necessary to use nuclear fusion reactions where deuterium, tritium and other light atomic nuclei fuse in a plasma state and become heavier atomic nuclei such as helium. Lithium, the raw material for tritium, and Deuterium are abundantly available in seawater. Additionally, the generation of fusion energy does not result in the generation of CO₂. For this reason, fusion energy is expected to fundamentally solve energy and environmental issues. See *5 regarding plasma.Utilizing the technologies and knowledge obtained through the production of the prototype, Hitachi and QST will continue to contribute to the promotion of the ITER Project and also cooperate in the development of technologies for realizing fusion energy in the future. In addition, Hitachi seeks to provide divertors and similar in-vessel components to fusion energy-related startups and a prototype fusion reactor for which QST is investigating the design.The second prototype outer vertical targetHigh-heat-load sample of an outer vertical targetOutline of ITER and divertorsTo realize fusion energy, seven regions including Japan, Europe, the United States, Russia, South Korea, China and India are promoting the ITER Project, a large international project aimed at conducting scientific and technological demonstrations of fusion. With the goal of achieving full operation through nuclear fusion burning, the ITER experimental reactor is under construction in Saint-Paul-les-Durance, France. Japan is taking on important roles such as the development and production of major pieces of ITER components including divertors and toroidal field coils (TF coils). QST is the ITER Project's agent in Japan and it promotes the procurement of equipment.The divertor is one of the most important components of a tokamak*3 and other magnetic confinement*4 fusion reactors. Divertors play an important role in maintaining the stability of the nuclear fusion reaction and exhausting impurities such as fuel residue and the helium generated by the nuclear fusion reaction in the reactor core plasma.*5 Divertors are the only tokamak devices capable of directly receiving plasma. They are used in a severe environment where they are exposed to heat load and particle load from the plasma. For this reason, special materials such as tungsten are used to make them. Tungsten has a high-melting-point but it is difficult to machine. Moreover, the plasma-facing surfaces are precisely shaped, requiring high-precision machining and assembly technologies to achieve the correct overall shape, inclination, steps and gaps that are accurate to 0.5 mm or less. It is believed that divertors are the hardest piece of the ITER in-vessel components to manufacture.*3 The method, represented by ITER and JT-60SA, retains an ultra-high temperature plasma that is more than 100 million degrees or higher within a strong magnetic field in a vacuum, and nuclear fusion reactions occur within the plasma. See *5 regarding plasma. See *11 for information about JT-60SA.*4 Fusion plasma is at very high temperature and cannot be kept in a conventional container, but it retains positively or negatively charged ions and characteristically becomes entangled in magnetic fields (lines of magnetic force). Using these characteristics, a magnetic confinement fusion reactor forms a basket-like magnetic field to retain plasma.*5 Plasma is one of the four basic states of matter. It is the fourth state next to solid, liquid and gas. When matter is exposed to very high temperatures or a strong electromagnetic field, atoms break down and separate to positively charged ions and negatively charged electrons, and they form plasma.The heat load on divertors reaches a maximum of 20 megawatts per square meter. This is equivalent to the surface heat load that an asteroid probe is exposed to when entering the atmosphere and much more than the surface heat load the space shuttle was subjected to. Outer vertical targets need to have a strong mechanical structure because they are subject to strong electromagnetic forces that can reach an approx. maximum of 16.5 tons. The establishment of technology for making divertors resistant to high heat loads and huge electromagnetic forces is a very important part of increasing the power output of fusion reactors, reducing the size of the reactors or increasing their magnetic fields in the future.Characteristics of the technology for the production of the second prototypeQST leads the manufacturers' material development efforts, regarding them as key technology for enabling divertors to withstand heat load that can be as high as 20 megawatts per square meter. Consequently, the company established methods of producing tungsten monoblocks*6 which do not break even under heat load, and copper alloy cooling pipes which are kept strong by maintaining high thermal conductivity while limiting the coarsening of their crystal grain. To bond these materials together, a brazing*7 technology that is resistant to high heat load has also been developed.*6 This is one of the components of the outer vertical targets that are a combination of tungsten, a metal that is resistant to heat load, and a copper buffer material.*7 A method of bonding metals. The technology uses a metal called a brazing material to bond base materials to each other. In contrast, welding is a method of bonding metals by welding a base material.By combining technologies and experience which are accumulated over many years in the nuclear energy business, Hitachi has developed a defect-free, high-quality welding technology for special materials and a non-destructive technology for inspecting restricted and complex shapes, and repeated demonstration testing has shown that Hitachi has achieved the high-precision machining and assembly technology that is accurate to 0.5 mm or less, a requirement of the ITER Organization. To rationalize production processes and costs, an automatic welding system optimized specially for divertors was introduced for welding thick, high-strength stainless steel. Instead of manual work, a robotic arm with a welding torch attached is combined with a device that controls the position of the object to be welded in synchronization with the movement of the robotic arm, resulting in higher quality welding at low cost.The special materials necessary for outer vertical targets are procured by QST from material manufacturers and are supplied to Hitachi which uses the special materials provided by QST to machine and assemble outer vertical targets in a strictly quality-controlled process. QST maintains and uses a high-temperature helium leak test facility*8 for the in-vessel components of fusion reactors that is the only one of its kind in Japan, and it independently conducts final tests to ensure the quality of the divertors.*8 The test facility uses helium gas to check for leaks with high precision at a high temperature of 250'C which is the environment that divertors will be used in.Initiatives implemented by Hitachi and QST to dateTo date, Hitachi and QST have been developing and manufacturing an ultra-high-voltage power supply system*9 with a voltage of 1 million volts for neutral beam injectors*10 for ITER. Currently, a system is being tested in Italy. Production of the devices to be delivered to France has commenced at Hitachi's factory. To realize fusion energy quickly, efforts are under way in Japan to reinforce neutral beam injectors for JT-60SA,*11 the world's largest superconducting tokamak device built jointly by Japan and Europe in parallel with the ITER Project.*9 The system supplies the power needed to actuate neutral beam injectors.*10  The device for injecting high-energy hydrogen atoms into plasma to heat the plasma. It heats the plasma to an ultra-high temperature of more than 100 million degrees, the temperature at which a nuclear fusion reaction occurs.*11  For information about JT-60SA, see the explanation about the JT-60SA Project on the website of the National Institutes for Quantum Science and Technology.Website about Hitachi's fusion businesshttps://www.hitachi.co.jp/products/energy/nuclear/accelerator/index.htmlAbout Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About LumadaAbout the National Institutes for Quantum Science and TechnologyThe National Institutes for Quantum Science and Technology (QST) was established in April 2016 to promote quantum science and technology in a comprehensive and integrated manner. QST leads the world in 3 fields of research and development. Research on Quantum Technology Basis aims to create high functionality materials and devices utilizing high end laser technology. Research on Quantum Biological science aims to elucidate biological processes based on quantum science and technology. Research on Innovative Diagnosis and Treatment for Cancer and Dementia and other symptoms aims to realize a society of healthy longevity through heavy ion therapy, high precision diagnosis utilizing PET and treatments using targeted isotope therapy. Furthermore, the operation and maintenance of 3GeV-class synchrotron radiation facility “NanoTerasu” will be conducted as a national center of core high radiation medical assistance with public-private partnership leading technical development and human resource development in radiation medicine. Visit us at https://www.qst.go.jp/Contact information for Hitachi, Ltd.Business ContactTaku OyamaProject Management GroupFusion and Accelerators Development CenterGroup Leader Senior EngineerHitachi, Ltd+81-294-55-3420taku.oyama.ke@hitachi.comContact information for National Institutes for Quantum Science and TechnologyBusiness & Media ContactQST International Affairs and Public Relations Section,Department of International Affairs and Public Relations+81-432-06-3026info@qst.go.jp Copyright 2025 JCN Newswire via SeaPRwire.com.

Showcasing a prototype LEO satellite communication terminal (*1) enabling high-speed, high-capacity communication in areas with limited cellular coverageTOKYO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp Corporation (herein after "Sharp") will exhibit at the 2nd SPEXA - International Space Business Expo, held at Tokyo Big Sight (Koto-ku, Tokyo) from Wednesday, July 30 to Friday, August 1. Sharp will showcase a LEO satellite communication terminal under development, leveraging its expertise in compact, lightweight design and communication technologies from smartphone development, along with supporting applications and field trial initiatives.Booth Image - Main Exhibits* LEO Satellite Communication Terminal (Reference Exhibit)Sharp will exhibit the terminal and introduce potential use cases such as real-time data transmission, location sharing, and remote control in areas with limited cellular connectivity, including maritime and mountainous regions. The terminal is also proposed as a solution for business continuity plan (BCP) during disasters. A conceptual ultra-compact model, designed for drone integration, will be presented as part of Sharp's efforts toward next-generation field solutions.* Satellite Operation Application (Reference Exhibit)A dedicated application supports the efficient operation and management of the LEO satellite communication terminal. It allows users to monitor terminal status, nearby obstacles, and satellite positioning. In case of a malfunction, the app provides troubleshooting guidance, streamlining maintenance tasks.* Field TrialsSharp will present field trials conducted using the compact and lightweight LEO satellite communication terminal, installed on vessels and vehicles. Through these tests, Sharp is accelerating development to ensure stable communication under various conditions by evaluating practical performance and identifying technical challenges.*1 A user terminal integrating a LEO satellite communication antenna and modem functions. LEO stands for Low Earth Orbit.- Exhibition LocationTokyo Big Sight, South Exhibition Hall – Satellite Data & Space Utilization Area, Booth No.S6-34- LEO Satellite Communication User Terminal Images *2 A method that enhances system reliability by duplicating the system and keeping one in standby. In the field of communications, it refers to a system that enables bidirectional communication.*3 A type of bidirectional communication in which transmission and reception are performed alternately.*4 The LEO satellite communication terminal supports dual carrier operation.This development has been funded by the National Institute of Information and Communications Technology (NICT) (JP012368G50501). Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, “KYORIN”) announced today that Eisai (Thailand) Marketing Co., Ltd. (“Eisai Thailand”), a subsidiary of Eisai, has launched overactive bladder treatment Beova® Tablets (generic name vibegron) in Thailand.In 2021, Eisai acquired exclusive development and marketing rights from KYORIN for the agent in ASEAN member states Thailand, the Philippines, Malaysia, and Brunei. Eisai Thailand submitted an application for marketing authorization in Thailand in March 2023, and received approval in June 2024. This launch is the first within Eisai’s licensed region. In addition to the release in Thailand, approval has also been obtained in the Philippines and Malaysia, with preparations underway for market entry.Overactive bladder (OAB) is a urological condition with trouble in pooling urine in the bladder. It's predominant symptom is an urge to urinate, which is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. One of the major problems of OAB is the fact that patients refrain from leaving the house due to anxiety about going to the bathroom, cannot get enough sleep at night, or face limitations in their daily activities, which could lead to significantly-reduced quality of life.Appropriate treatment is necessary for OAB, which increases with age but has also been reported to becaused by brain or spinal cord disorders such as cerebrovascular diseases (cerebral hemorrhage and cerebral infarction), Parkinson's disease, and benign prostatic hyperplasia.1 The prevalence of OAB in Thailand is reported to be 15.8%.2This agent is a selective B3-adrenergic receptor agonist administered once daily, acting selectively on B3 receptors in the bladder, relaxing the bladder to enhance urine collection, and consequently improving the symptoms of urgency, urinary frequency and urge urinary incontinence associated with OAB.In September 2009, KYORIN and Eisai signed a license agreement for the development and marketing in Asia of Uritos® Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, discovered and developed by KYORIN, and as of today Eisai sells Uritos in Thailand, the Philippines, Indonesia, Cambodia, Vietnam, Laos and Myanmar. In addition to Uritos, Eisai will provide patients with new treatment options for OAB through the launch of Beova in Thailand and make further contributions to improving the quality of life and increasing benefits to patients with OAB in Asia.1. About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target(3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com, and connect with us on X, LinkedIn and Facebook. 2. About KYORIN Pharmaceutical Co., Ltd.KYORIN operates under the corporate philosophy, "KYORIN continues to fulfil it's mission of cherishing life and benefiting society by contributing to better health." Based on this principle, we aim to continuously provide high-valuenew drugs that meet medical needs, striving to become a company that contributes broadly to people's health. In drug discovery, we focus our research efforts on the therapeutic areas of pain and autoimmune disorders etc., working to create innovative new drugs that meet significant medical needs. In sales, we implement a Franchise Customer (FC) strategy, concentrating our resources on specialized areas, respiratory, otolaryngology, and urology.For more information on KYORIN Pharmaceutical Co., Ltd., please visit https://www.kyorin-pharm.co.jp/en/.3. About vibegronVibegron was discovered by Merck & Co., Rahway, N.J., U.S.A. (known as MSD outside of the United States and Canada) as a once-daily oral treatment for overactive bladder (OAB), which acts selectively on the bladder's B3-adrenergic receptor agonists. Vibegron selectively acts on B3 receptors in the bladder and increases bladder capacity by enhancing the bladder-relaxing effect of noradrenaline during the urinary storage phase, resulting in the improvement of incontinence symptoms of urinary urgency, frequent urination and urge urinary incontinence with OAB. KYORIN has obtained exclusive rights for developing, manufacturing and marketing of this drug in Japan (July 2014) and Asia* (April2017) from Merck & Co., Inc., Rahway, N.J., U.S.A.In Eisai’s licensed territories (Thailand, the Philippines, Malaysia and Brunei), in addition to it's new launch in Thailand, approvals have been obtained in the Philippines and Malaysia, with preparations underway for market entry. In Japan, KYORIN and Kissei have jointly developed the agent locally under a co-development and co-marketing agreement entered into as of March 2016. Since November 2018, the two companies have been jointly marketing it under the product name of “Beova® Tablets 50mg”.*South Korea, Taiwan, Hong Kong, and 10 member states of ASEAN1 Clinical Guidelines for Overactive Bladder Syndrome 3rd Edition (Japanese only)2 ICS2024 Abstract 554 https://www.ics.org/2024/abstract/554Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81-(0)3-3817-5120KYORIN Pharmaceutical Co., Ltd.Corporate PlanningTEL: +81-(0)3-6374-9702   Copyright 2025 JCN Newswire via SeaPRwire.com.

SAN DIEGO, July 23, 2025 - (JCN Newswire via SeaPRwire.com) - Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, announced today that its San Diego laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This significant milestone enables Crown Bioscience to deliver clinical-grade testing, further strengthening its support for clients' clinical and translational drug development efforts.CLIA, regulated by the Centers for Medicare and Medicaid Services (CMS), sets rigorous federal standards for accuracy, reliability, and quality laboratory operations. With this designation, Crown Bioscience’s San Diego facility affirms full compliance, providing clients with increased confidence in the biomarker data used for clinical decision-making and regulatory submissions."Achieving this marks a crucial step in our commitment to delivering high-quality, compliant laboratory services," said Julie Mayer, Vice President, Global Biomarker Platform at Crown Bioscience. "This enables us to expand our offerings by leveraging CLIA certification to support our partners in accelerating their clinical development and regulatory approval timelines."As a CLIA-certified laboratory, Crown Bioscience is now equipped to conduct clinical testing on human specimens, a key component of advancing oncology research and personalized medicine. This designation strengthens the company’s position as a trusted partner capable of meeting specialized project needs throughout all stages of drug development.For more information about Crown Bioscience’s certifications and accreditations, please visit the company’s website.About Crown BioscienceCrown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit www.crownbio.com.Media Inquiries:Crown BioscienceSarah Martin-Tyrrellpr@crownbio.com Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO, July 22, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced the termination of its engine business operation at Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd. (hereinafter, SAME) in China and has terminated the joint venture partnership.Established in August 1997, SAME began engine production in 1998 and has played a key role in China’s expanding automotive market by supplying engines not only to Mitsubishi-branded vehicle manufacturers, but also to numerous Chinese automakers. However, in response to the rapid transformation of China’s automotive industry, Mitsubishi Motors has reassessed its strategy in the region and has decided to terminate its participation in the joint venture.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society. For more information on Mitsubishi Motors, please visit the company's website athttps://www.mitsubishi-motors.com/en/ Copyright 2025 JCN Newswire via SeaPRwire.com.

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab longterm data, an immunoassay for measuring amyloid-B protofibrils in cerebrospinal fluid, and asubcutaneousl form of lecanemab for continued treatment of ADAD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque depositionTOKYO, July 22, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. Eisai will present 21 oral presentations, 24 posters, three (3) symposia and two (2)lecanemab product theaters.Key Oral Lecanemab Presentations• Four-year Data: On Wednesday July 30 (8:00 – 8:45 AM EDT), as part of the “Developing Topics Session: Innovative Therapeutic Approaches”, initial four-year findings will be presented on lecanemab from the Phase III Clarity AD Open-Label Extension in Early Alzheimer's Disease trial.• Subcutaneous Maintenance Dosing: A Featured Research Session on Wednesday, July 30 (9:00 –10:30 AM EDT) will include data on the potential of a new and convenient option for ongoing lecanemab treatment, the subcutaneous formulation for maintenance dosing.• Real World Case Studies: A Developing Topics Session on Sunday, July 27 (9:00 – 10:30 AM EDT) will include data on real-world case studies and patient pathway learnings from diverse U.S. clinical settings two years post-approval of lecanemab.Key Lecanemab Poster Presentation• A Poster Presentation on Monday, July 28 (viewing available from 7:30 AM – 4:15 PM EDT) will share findings on cerebrospinal fluid (CSF) samples collected from the Clarity AD trial and analyzed using the novel, sensitive immunoassay developed to measure amyloid-B protofibrils in CSF.Key Oral E2814 Presentation• A Featured Research Session on Wednesday, July 30 (4:15 PM – 5:45 PM EDT) will include findings from “Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer’s Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial.”“The data presented at AAIC 2025 will highlight long-term findings from lecanemab’s open-label extension trial, real-world lecanemab case studies as well as results on a subcutaneous formulation and dosing regimen that may offer patients more flexibility to continue treatment to fight Alzhierm’s disease,” said LynnD. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. “Eisai will also share preliminary results from the DIAN-TU-001 NexGen Trial, exploring etalanetug with background lecanemab therapy to slow or prevent the progression of Alzhierm’s disease. As we gain more experience using dual-acting lecanemab in different clinical settings and continue to explore new avenues to improve the diagnosis and treatment of Alzhierm’s disease, we are hopeful about the future. We remain committed to patients and their loved ones who are impacted by this progressive, relentless disease, caused by a continuous underlying neurotoxic process that begins before and continues after plaque is removed from the brain.”For more details, please visit: https://www.eisai.com/news/2025/pdf/enews202548pdf.pdf     Copyright 2025 JCN Newswire via SeaPRwire.com.